Notice: This company has been marked as potentially delisted and may not be actively trading. Range Cancer Therapeutics ETF Rating Add Compare Share Share Ratings Stock AnalysisHeadlinesHoldingsRatingsShort InterestTrends Range Cancer Therapeutics ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.CNCR Aggregate RatingModerate Buy 2.78Holdings in CNCR have an aggregate rating of Moderate Buy based on 493 analyst ratings issued in the past year covering 50 companies (80.0% of the portfolio).CNCR Aggregate Price Target$12.34High Prediction$12.34Average Prediction$12.34Low Prediction$12.34Holdings in CNCR have an aggregate price target of $12.34 and a range of $12.34 to $12.34 covering 50 companies (80.0% of the portfolio).CNCR Consensus Ratings of HoldingsStrong Buy1 Strong Buy rating(s)Buy22 Buy rating(s)Moderate Buy21 Moderate Buy rating(s)Hold5 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Range Cancer Therapeutics ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 50 CNCR Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings3.75%DNAGinkgo Bioworks$10.86-5.0%0.8367 of 5 stars1.60$4.58 -57.9%5Upcoming EarningsNews CoverageGap Up3.72%RXRXRecursion Pharmaceuticals$9.28-10.3%1.5061 of 5 stars2.50$8.75 -5.7%43.36%CMPXCompass Therapeutics$2.92-5.2%3.3229 of 5 stars2.75$11.29 286.5%8Analyst ForecastGap Up2.79%PGENPrecigen$1.91-3.0%3.9293 of 5 stars2.60$7.00 266.5%52.76%GNLXGenelux$4.84+0.4%1.1759 of 5 stars3.20$18.25 277.1%52.29%VORVor Biopharma$1.37-2.1%2.186 of 5 stars3.00$11.36 729.0%7Negative News2.19%REPLReplimune Group$13.98-2.3%4.0689 of 5 stars3.13$19.29 38.0%8Gap Up2.12%SDGRSchrödinger$22.64-5.7%1.9377 of 5 stars2.80$32.11 41.8%10Upcoming Earnings2.00%BPMCBlueprint Medicines$92.25-2.2%3.0079 of 5 stars2.65$123.83 34.2%20Earnings ReportAnalyst Upgrade2.00%EXELExelixis$36.85+5.0%4.617 of 5 stars2.55$37.24 1.0%20Analyst UpgradeInsider Trade1.97%GLUEMonte Rosa Therapeutics$6.22-6.2%2.6699 of 5 stars2.67$14.00 125.1%3Positive News1.87%ZYMEZymeworks$14.39+2.6%2.097 of 5 stars2.86$19.17 33.2%71.87%BMYBristol-Myers Squibb$55.85+0.1%4.5826 of 5 stars2.30$57.86 3.6%20Analyst RevisionPositive News1.86%SWTXSpringWorks Therapeutics$58.29-2.7%1.2357 of 5 stars3.00$71.50 22.7%6Earnings ReportAnalyst ForecastInsider TradeAnalyst RevisionNews Coverage1.61%ELVNEnliven Therapeutics$21.80+1.5%1.8006 of 5 stars3.20$38.25 75.5%51.58%IBRXImmunityBio$3.42-6.0%2.0686 of 5 stars3.00$13.58 297.2%4News Coverage1.56%BNTXBioNTech$120.01+1.8%2.4283 of 5 stars2.88$142.72 18.9%17Positive NewsHigh Trading Volume1.55%RVMDRevolution Medicines$41.34-2.2%4.5088 of 5 stars3.08$66.25 60.3%121.49%IMCRImmunocore$29.92+0.2%1.4182 of 5 stars2.54$65.64 119.4%131.45%DAWNDay One Biopharmaceuticals$12.43+1.6%1.8467 of 5 stars3.00$35.71 187.3%9Upcoming EarningsInsider TradeNews Coverage1.43%ACLXArcellx$63.75-2.8%2.0088 of 5 stars3.13$105.93 66.2%15Upcoming Earnings1.40%SNDXSyndax Pharmaceuticals$16.38+2.4%3.7131 of 5 stars2.90$36.20 121.0%101.39%IPHAInnate Pharma$2.24-0.9%2.9545 of 5 stars3.50$11.50 413.4%2News CoverageGap Up1.35%MRUSMerus$47.37-0.5%2.9177 of 5 stars3.13$85.92 81.4%161.35%KPTIKaryopharm Therapeutics$0.60-1.9%3.7781 of 5 stars3.00$5.00 735.6%4Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage1.32%XNCRXencor$15.74-0.3%3.4736 of 5 stars3.13$34.88 121.6%81.31%HCMHUTCHMED$16.11+5.1%1.5946 of 5 stars2.00$19.00 17.9%1News CoverageGap UpHigh Trading Volume1.29%JANXJanux Therapeutics$36.01-3.1%3.1259 of 5 stars3.08$89.90 149.7%131.28%AURAAura Biosciences$7.51-1.6%3.2136 of 5 stars3.29$23.00 206.3%71.27%NUVBNuvation Bio$2.21-2.9%2.0414 of 5 stars3.00$8.20 271.9%51.26%KYMRKymera Therapeutics$36.81-1.6%2.3473 of 5 stars2.88$55.06 49.6%17News CoverageGap Up1.25%NUVLNuvalent$79.49-3.5%2.1107 of 5 stars2.86$112.36 41.4%14Upcoming EarningsInsider Trade1.24%MGNXMacroGenics$2.76-4.2%3.5716 of 5 stars2.36$7.63 176.3%11News Coverage1.22%NRIXNurix Therapeutics$16.87-1.0%1.5527 of 5 stars2.94$31.81 88.6%161.22%ARVNArvinas$17.77-3.3%3.0723 of 5 stars3.00$60.00 237.6%12Gap Up1.22%RCUSArcus Biosciences$11.06+3.0%2.6114 of 5 stars2.90$29.50 166.7%10Analyst ForecastAnalyst RevisionNews CoverageGap Up1.21%MRKMerck & Co., Inc.$89.40+2.0%5 of 5 stars2.58$116.39 30.2%24Analyst DowngradeOptions Volume1.20%ACRVAcrivon Therapeutics$5.54-5.3%2.3308 of 5 stars3.00$23.67 327.2%8Short Interest ↓1.19%INBXInhibrx$12.56-1.9%1.8072 of 5 stars2.001Short Interest ↓1.17%GMABGenmab A/S$22.34-0.4%4.585 of 5 stars2.75$42.17 88.7%121.13%LEGNLegend Biotech$39.70+2.0%2.523 of 5 stars3.00$79.50 100.3%12News Coverage1.12%SMMTSummit Therapeutics$22.12-4.1%2.3269 of 5 stars2.86$33.57 51.8%71.10%GERNGeron$2.58-2.1%3.0082 of 5 stars3.08$6.91 168.3%12Analyst ForecastAnalyst RevisionNews Coverage1.09%IMRXImmuneering$1.81+5.6%3.0153 of 5 stars2.38$12.20 575.9%81.09%CRBUCaribou Biosciences$1.31-7.1%3.1284 of 5 stars3.00$10.33 688.8%51.06%ACETAdicet Bio$0.97-2.7%2.3736 of 5 stars2.60$7.50 670.5%5Gap Up1.03%TYRATyra Biosciences$13.17+3.1%1.6187 of 5 stars3.00$30.50 131.6%6Analyst Forecast1.03%ITOSiTeos Therapeutics$7.41-0.9%3.1935 of 5 stars3.00$22.25 200.3%41.02%IDYAIDEAYA Biosciences$21.75+0.1%3.8191 of 5 stars2.93$53.58 146.4%15Gap Up1.01%REGNRegeneron Pharmaceuticals$700.33+0.6%4.7594 of 5 stars2.76$973.13 39.0%25Dividend Announcement This page (NASDAQ:CNCR) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Range Cancer Therapeutics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Range Cancer Therapeutics ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
